Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Verastem Oncology

< Previous 1 2 3 4 Next >

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 04, 2024

From Verastem Oncology

Via Business Wire

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

March 18, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

March 14, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

March 11, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

March 05, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

March 05, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

January 29, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

January 18, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

January 11, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 05, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

December 18, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

December 13, 2023

From Verastem Oncology

Via Business Wire

New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

November 13, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 08, 2023

From Verastem Oncology

Via Business Wire

First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer

November 07, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

November 06, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

October 26, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 18, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer

October 14, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 06, 2023

From Verastem Oncology

Via Business Wire

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

September 28, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology to Participate in Upcoming Investor Conferences

September 05, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

August 28, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

August 08, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer

July 11, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

July 05, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants

June 16, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 15, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Reverse Stock Split

May 31, 2023

From Verastem Oncology

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.